These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38822321)

  • 1. Clinical application of serum tumor abnormal protein in prostate cancer patients.
    Fu L; Zhang C; Wang Z; Tao W; Zhu J; Zhou Y; Sun C; Xue B; Yu M; Xu L; Zang Y
    BMC Cancer; 2024 May; 24(1):665. PubMed ID: 38822321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
    Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
    Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
    Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
    Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer.
    Smrkolj T; Gubina B; Bizjak J; Kumer K; Fabjan T; Osredkar J
    Adv Clin Exp Med; 2017 Oct; 26(7):1085-1090. PubMed ID: 29211355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA).
    Ceriani L; Giovanella L; Salvadore M; Bono AV; Roncari G
    Int J Biol Markers; 1997; 12(1):27-34. PubMed ID: 9176715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
    Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
    Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen ratio correlates with aggressiveness of histology grades of prostate cancer.
    Li W; Ren Y; Mee V; Wong PY
    Clin Biochem; 1999 Feb; 32(1):31-7. PubMed ID: 10074889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
    Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
    Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
    Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
    Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated prostate specific antigen and reduced 10-year survival among a cohort of Danish men consecutively referred from primary care to an urological department during 2005-2006.
    Hillig T; Nielsen TK; Hansen SI; Nygaard AB; Sölétormos G
    Scand J Clin Lab Invest; 2017 Feb; 77(1):27-35. PubMed ID: 27762145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
    Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels.
    Izumi K; Ikeda H; Maolake A; Machioka K; Nohara T; Narimoto K; Ueno S; Kadono Y; Kitagawa Y; Konaka H; Mizokami A; Namiki M
    Prostate; 2015 Jul; 75(10):1034-42. PubMed ID: 25753899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6.
    Wang H; Gu L; Wu Y; Feng D; Duan J; Wang X; Huang Y; Wu S; Chen J; Luo G; Zhang X
    BMC Cancer; 2017 Sep; 17(1):629. PubMed ID: 28874127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum free prostate-specific antigen in the diagnosis of prostate cancer.
    Leung HY; Lai LC; Day J; Thomson J; Neal DE; Hamdy FC
    Br J Urol; 1997 Aug; 80(2):256-9. PubMed ID: 9284198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate.
    Kapoor N; Jain R; Surange S; Bhardwaj VK; Srivastava A
    Indian J Pathol Microbiol; 2006 Apr; 49(2):178-81. PubMed ID: 16933710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.